ALK and non-small cell lung carcinoma: This was a randomized, double-blind, placebo-controlled, phase III trial to evaluate toripalimab (an anti-PD1 ICI) plus chemotherapy (three cycles before surgery and one after) followed by toripalimab maintenance for a year vs. chemotherapy alone in resectable stage II/III NSCLC, without EGFR/ALK alterations.